{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:18:57Z","timestamp":1791451137472,"version":"4.3.3"},"reference-count":40,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.25459","type":"journal-article","created":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T16:00:31Z","timestamp":1661529631000},"page":"e2225459","source":"Crossref","is-referenced-by-count":68,"title":["Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival Among Patients With Metastatic Melanoma in the Anti\u2013PD-1 Era"],"prefix":"10.1001","volume":"5","author":[{"given":"Nayan","family":"Lamba","sequence":"first","affiliation":[{"name":"Harvard Radiation Oncology Program, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Ott","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Bryan","family":"Iorgulescu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,8,25]]},"reference":[{"issue":"10151","key":"zoi220711r1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma.","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"issue":"12","key":"zoi220711r2","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1007\/s00262-018-2241-x","article-title":"Management of metastatic melanoma: improved survival in a national cohort following the approvals of checkpoint blockade immunotherapies and targeted therapies.","volume":"67","author":"Dobry","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"zoi220711r3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.6004\/jnccn.2016.0101","article-title":"NCCN Guidelines insights: melanoma, version 3.2016: featured updates to the NCCN Guidelines.","volume":"14","author":"Coit","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"zoi220711r4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejca.2017.07.022","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur J Cancer"},{"issue":"8","key":"zoi220711r5","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"14","key":"zoi220711r6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi220711r7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi220711r8","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial.","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi220711r9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi220711r10","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi220711r12","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/CMR.0000000000000672","article-title":"Utilization and impact of immunotherapy in stage IV melanoma using the National Cancer Database.","volume":"30","author":"Conic","year":"2020","journal-title":"Melanoma Res"},{"issue":"12","key":"zoi220711r13","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","article-title":"Using the National Cancer Database for outcomes research: a review.","volume":"3","author":"Boffa","year":"2017","journal-title":"JAMA Oncol"},{"issue":"6","key":"zoi220711r14","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1245\/s10434-019-07213-1","article-title":"Incident cases captured in the National Cancer Database compared with those in U.S. population based central cancer registries in 2012-2014.","volume":"26","author":"Mallin","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"zoi220711r15","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1158\/2326-6066.CIR-18-0067","article-title":"Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort.","volume":"6","author":"Iorgulescu","year":"2018","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"zoi220711r16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"zoi220711r17","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"zoi220711r18","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol"},{"issue":"16","key":"zoi220711r19","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi220711r20","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"36_suppl","key":"zoi220711r21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.36_suppl.356154","article-title":"DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): a phase III trial\u2014ECOG-ACRIN EA6134.","volume":"39","author":"Atkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi220711r22","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi220711r23","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"zoi220711r24","doi-asserted-by":"publisher","first-page":"CNS33","DOI":"10.2217\/cns-2018-0018","article-title":"Efficacy and safety of immune checkpoint blockade for brain metastases.","volume":"8","author":"Harary","year":"2019","journal-title":"CNS Oncol"},{"issue":"1","key":"zoi220711r25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.18.00204","article-title":"Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial.","volume":"37","author":"Kluger","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi220711r26","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain.","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi220711r27","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/cam4.v10.4","article-title":"Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases.","volume":"10","author":"Moyers","year":"2021","journal-title":"Cancer Med"},{"issue":"1","key":"zoi220711r28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-020-03663-w","article-title":"Time from stereotactic radiosurgery to immunotherapy in patients with melanoma brain metastases and impact on outcome.","volume":"152","author":"Wegner","year":"2021","journal-title":"J Neurooncol"},{"issue":"9","key":"zoi220711r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.15656","article-title":"Association of sociodemographic factors with immunotherapy receipt for metastatic melanoma in the US.","volume":"3","author":"Moyers","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"11","key":"zoi220711r30","doi-asserted-by":"publisher","first-page":"2614","DOI":"10.1002\/cncr.32817","article-title":"Use of immunotherapy and surgery for stage IV melanoma.","volume":"126","author":"Molina","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"zoi220711r31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s40425-019-0782-y","article-title":"Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma.","volume":"7","author":"Krimphove","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"zoi220711r32","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11060-019-03171-6","article-title":"Survival and prognostic factors in surgically treated brain metastases.","volume":"143","author":"Kavouridis","year":"2019","journal-title":"J Neurooncol"},{"issue":"3","key":"zoi220711r33","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.ijrobp.2020.07.2108","article-title":"Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: a phase III randomized controlled trial.","volume":"108","author":"Li","year":"2020","journal-title":"IJROBP"},{"issue":"2","key":"zoi220711r34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi220711r35","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/S1470-2045(17)30441-2","article-title":"Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C\/CEC\u00b73): a multicentre, randomised, controlled, phase 3 trial.","volume":"18","author":"Brown","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi220711r36","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/S1470-2045(17)30414-X","article-title":"Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial.","volume":"18","author":"Mahajan","year":"2017","journal-title":"Lancet Oncol"},{"issue":"22","key":"zoi220711r37","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1200\/JCO.19.00189","article-title":"Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications.","volume":"37","author":"Ricciuti","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"zoi220711r38","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/neuonc\/noab046","article-title":"The combined use of steroids and immune checkpoint inhibitors in brain metastasis patients: a systematic review and meta-analysis.","volume":"23","author":"Jessurun","year":"2021","journal-title":"Neuro Oncol"},{"issue":"7","key":"zoi220711r39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002261","article-title":"Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer.","volume":"9","author":"Maslov","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"1","key":"zoi220711r40","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1158\/1078-0432.CCR-20-2291","article-title":"Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma.","volume":"27","author":"Iorgulescu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"zoi220711r11","unstructured":"National Comprehensive Cancer Network. Melanoma cutaneous (version 2.2021). Accessed January 10, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2795637\/lamba_2022_oi_220711_1660829915.27318.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,26]],"date-time":"2022-08-26T16:00:34Z","timestamp":1661529634000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2795637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,25]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.25459","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,25]]}}}